about
Preparation and characterization of drug-loaded polymethacrylate microspheres by an emulsion solvent evaporation method.Biocompatible Polyhydroxyethylaspartamide-based Micelles with Gadolinium for MRI Contrast AgentsEnhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process.Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxideOptimized formulation of solid self-microemulsifying sirolimus delivery systemsBiodistribution of newly synthesized PHEA-based polymer-coated SPION in Sprague Dawley rats as magnetic resonance contrast agentLiposomal drug products and recent advances in the synthesis of supercritical fluid-mediated liposomes.In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth.Comparative study of telmisartan tablets prepared via the wet granulation method and pritor™ prepared using the spray-drying method.pH-independent sustained release matrix tablet containing doxazosin mesylate: effect of citric acid.Bioavailability of indomethacin-saccharin cocrystals.Solid-state carbon NMR characterization and investigation of intrinsic dissolution behavior of fluconazole polymorphs, anhydrate forms I and II.Quantitative determination of sirolimus in dog blood using liquid chromatography-tandem mass spectrometry, and its applications to pharmacokinetic studies.Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process.Enhanced dissolution of megestrol acetate microcrystals prepared by antisolvent precipitation process using hydrophilic additives.Pharmacokinetic and bioequivalence study of itopride HCl in healthy volunteers.Enhancement of wettability and dissolution properties of cilostazol using the supercritical antisolvent process: effect of various additives.Design of pH-independent extended release matrix tablets of minocycline hydrochloride for the treatment of dementia.Enhanced solubility and oral absorption of sirolimus using D-α-tocopheryl polyethylene glycol succinate micelles.Quality by design: screening of critical variables and formulation optimization of Eudragit E nanoparticles containing dutasteride.Preparation of alginate beads for floating drug delivery system: effects of CO(2) gas-forming agents.Preparation and characterization of chitosan microparticles intended for controlled drug delivery.Preparation and release characteristics of polymer-coated and blended alginate microspheres.Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.Chitosan microparticle preparation for controlled drug release by response surface methodology.Hydrogel patches containing triclosan for acne treatment.Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process.Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers.The influence of Surelease and sodium alginate on the in-vitro release of tamsulosin hydrochloride in pellet dosage form.Reparation of controlled release spheronized beads by simple extrusion and modified spheronization process.Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.Supersaturatable formulations for the enhanced oral absorption of sirolimus.Characteristics of felodipine-located poly(epsilon-caprolactone) microspheres.Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process.Influence of the delivery systems using a microneedle array on the permeation of a hydrophilic molecule, calcein.Paroxetine hydrochloride controlled release POLYOX matrix tablets: screening of formulation variables using Plackett-Burman screening design.Preparation and characterization of solid dispersions of itraconazole by using aerosol solvent extraction system for improvement in drug solubility and bioavailability.Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.Controlled release tamsulosin hydrochloride from alginate beads with waxy materials.Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids.
P50
Q31129916-FF8ADE24-EDB9-4384-A23B-B02DAB81EFB9Q34347408-0206A819-2B5B-4EA2-9147-9A08DD857A51Q35592271-E22CEA28-7C3A-4BBB-96E0-725C842B2E75Q36358743-BD3ADCFD-5D90-4C51-BDC3-D3039EBC01F4Q36805040-8A093777-C2BB-4A13-A208-F4F325C5B28AQ37278614-E472F5DD-58FE-434F-8019-8D3A76FC50C0Q38132414-37A81F55-6227-4A86-8194-3DD50904DB1BQ39726118-964C3691-E9B9-4A49-94D9-E60FAF21DA6FQ39753341-5A1AE253-3734-4C3E-9889-5B7DAF1761E1Q42769915-E00B7E00-D9EF-43D7-A48E-7488A19D339BQ42840455-33BE9103-AB80-46B9-9602-22419EEBA514Q42914571-C0FA1730-DD72-4002-A462-11B2781095EEQ42950844-07B1C07F-5743-4A40-9C12-BED59AAE3F63Q42990131-33BD31FE-CB4C-44B6-96DC-185985FCD2E6Q43014353-DBA1882D-5E28-4296-AAB1-7918442D8345Q43084287-A8E7E166-83AA-47B4-96A1-3692441782CAQ43179303-5291FBF5-7FCC-4EA9-BBB8-86987A437EF0Q43187612-C7610C7B-E608-46B4-B6DC-C8D9AB525F42Q43410189-F473E175-D6A5-4091-8040-F88AFAD23ABEQ43978588-2A9EFB1C-AB37-43E1-8D7B-526E86BD16FEQ44019794-4099A5BD-8DAB-47DA-9285-3EF0DB3A00DEQ44217537-6CAAFC03-A16E-4C72-8B59-51D07DAADAC3Q44294439-D73D22C9-5D7A-4505-A099-225991EE82EEQ44330532-572E554A-1F6C-49AF-9A06-8FB8098343E1Q44640333-BB58F21F-7A33-47C3-AA86-478D01B4AC6BQ44645216-88AC1D79-0D5F-43C4-9780-6FB55B2E31D2Q45082005-9EB22D56-623F-4F9D-BBAB-65FB64537575Q46355032-2C7618BB-82B2-4B2B-BC14-0B363CF3868DQ46559881-3F6787AC-2135-4243-8518-BE6E053E6618Q46563083-653CE671-62EB-4BA1-9AE4-08AD79206121Q46577097-CE527673-2FC1-41F4-8B03-38134E561ABFQ46586517-82580BDB-7C45-4F85-A052-B97762E17917Q46601030-DAD095CA-A11A-4C51-A881-42685D48499FQ46604415-EAA09C2F-B834-42B6-A56E-157357D018CAQ46645701-BC5B23FC-7FD4-40EF-A956-0D9CC8B4A645Q46647331-F39EF16F-A76E-4658-B958-C28FC4F0BEDEQ46662356-B7978B94-DB18-41E8-8306-975A7A4DF868Q46688330-2BA55461-3B62-425E-A397-D3FB98322F22Q46851051-0986AFA9-A37A-4080-99D6-0F15F67C1F75Q46851055-64CAC734-A673-4AD3-A787-F4889602FCCD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sung-joo Hwang
@ast
Sung-joo Hwang
@en
Sung-joo Hwang
@es
Sung-joo Hwang
@nl
Sung-joo Hwang
@sl
type
label
Sung-joo Hwang
@ast
Sung-joo Hwang
@en
Sung-joo Hwang
@es
Sung-joo Hwang
@nl
Sung-joo Hwang
@sl
prefLabel
Sung-joo Hwang
@ast
Sung-joo Hwang
@en
Sung-joo Hwang
@es
Sung-joo Hwang
@nl
Sung-joo Hwang
@sl
P106
P31
P496
0000-0001-6521-3822